ELI LILLY & Co
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
Basic company information
Each field links to its source. Financial figures retain their reporting periods; background references are identified in the source list.
- Ticker / security symbols
- LLY [1]
- Listing exchanges
- NYSE [1]
- SEC industry
- Pharmaceutical Preparations [1]
- Business sectors
- pharmaceutical industry [2]
- Company / filing name
- ELI LILLY & Co [1]
- Headquarters location
- Indianapolis [2]
- Business address
- LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, 46285 [1]
- Founded
- 1901; 1875 [2]
- Incorporation jurisdiction
- Indiana, United States [1]
- Leadership in background record
- David A. Ricks [2]
- Founders
- Eli Lilly [2]
- Official website
- www.lilly.com ↗ [2]
- Employees
- 38,350 · reported year 2018 [2]
- Annual revenue
- USD 65,179,000,000 · 2025-01-01 to 2025-12-31 [3]
- Total assets
- USD 112,476,000,000 · at 2025-12-31 [3]
- Net income / loss
- USD 20,640,000,000 · 2025-01-01 to 2025-12-31 [3]
- Fiscal year end
- December 31 (SEC record) [1]
- ISIN (reported securities)
- US5324571083 [2]
- CIK
- 0000059478 [1]
- SIC code
- 2834 [1]
- Country in background record
- United States [2]
Company positioning and business
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. [4]
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. [4]
The company's primary products are tirzepatide (Mounjaro and Zepbound) for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea (56% of 2025 revenues); abemaciclib (Verzenio) for the treatment of advanced or metastatic breast cancers (9% of 2025 revenues); dulaglutide (Trulicity) for the treatment of type 2 diabetes (7% of 2025 revenues); ixekizumab (Taltz) for the treatment of autoimmune diseases (6% of 2025 revenues); and empagliflozin (Jardiance) for the treatment of type 2 diabetes (5% of 2025 revenues). Products that have a minor contribution to revenues include Insulin lispro (Humalog), a modified type of medical insulin; ramucirumab (Cyramza), a fully human monoclonal antibody used for the treatment of cancer; baricitinib (Olumiant), an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19; insulin (Humulin) to treat high blood glucose; and galcanezumab (Emgality), a humanized monoclonal antibody used for the prevention of migraines. In 2024, 67% of the company's revenues came from the United States, 18% came from Europe, 3% came from Japan, and 3% came from China. [4]
Background text: Wikipedia contributors, Eli Lilly and Company. Selected introductory paragraphs, licensed under CC BY-SA 4.0. Official filing data is cited separately.
Management and corporate governance
The Wikidata background record identifies David A. Ricks in the chief-executive role. This background entry is not an official confirmation of the current board or executive roster. [2]
Understanding company scale
Revenue: USD 65,179,000,000, 2025-01-01 to 2025-12-31. Reported in Form 10-K filed 2026-02-12. Figures are consolidated XBRL facts; reporting periods and amendments must be checked before comparing companies. [3]
Net income / loss: USD 20,640,000,000, 2025-01-01 to 2025-12-31. Reported in Form 10-K filed 2026-02-12. Figures are consolidated XBRL facts; reporting periods and amendments must be checked before comparing companies. [3]
Total assets: USD 112,476,000,000, at 2025-12-31. Reported in Form 10-K filed 2026-02-12. Figures are consolidated XBRL facts; reporting periods and amendments must be checked before comparing companies. [3]
Financial year, securities and disclosures
The SEC submissions record gives ELI LILLY & Co a fiscal year end of 1231 (MMDD). Individual filings below identify their own reporting period; the filing date is the publication event, not the financial year end. [1]
Listed securities: LLY (NYSE). Multiple symbols may represent different share classes or securities of the same registrant. [5]
History and key events
Form 10-K filed; reporting period ends 2025-12-31. [6]
Financial results and regulatory disclosures
Annual, quarterly and current reports from the collected SEC record. Insider Forms 4 and 144 are excluded. This is a selected list, not a live filing feed.
Source-verified relationships
Companies in the same industry
Comparison candidates share the SEC SIC classification 2834. This does not imply ownership, partnership or trading relationships.
Related entities and concepts
Frequently asked questions
When was ELI LILLY & Co founded?
Founded: 1901; 1875. The linked source provides the background record. [2]
Where is the headquarters of ELI LILLY & Co?
Headquarters location: Indianapolis. The linked source provides the background record. [2]
Which business sectors are recorded for ELI LILLY & Co?
Business sectors: pharmaceutical industry. The linked source provides the background record. [2]
ELI LILLY & Co relationship map
Select a node to inspect its relationship and source.
2 verified direct relationships. Industry peers are not relationship edges.
Sources and review dates
- SEC — ELI LILLY & Co filing identity and securities ↗
- Wikidata — company background record (CC0) ↗
- SEC — ELI LILLY & Co reported financial facts ↗
- Wikipedia contributors — Eli Lilly and Company (CC BY-SA 4.0) ↗
- SEC securities directory ↗
- Company chronology / filing ↗
Reviewed 23 October 2026. Financial periods and historical event dates are shown separately. Figures reflect their stated source dates; this page is not a live quote or investment recommendation.